Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes

Medicine and Dentistry

• Glucose 100%
• Maturity Onset Diabetes of the Young 100%
• Cardiovascular System 40%
• Cardiovascular Disease 40%
• Cardiovascular Risk 40%
• Thiazolidinedione 40%
• Drug Combination 40%
• Drug 40%
• Chemotherapeutic Agent 40%
• Medication 40%
• Morbidity 20%
• Glycemic Control 20%
• Hemoglobin A1c 20%
• Hypoglycemia 20%
• Diabetes Mellitus 20%
• Myocardial Infarction 20%
• Sulfonylurea 20%
• Glycon 20%
• Sodium Glucose Cotransporter 2 Inhibitor 20%
• Glucagon-Like Peptide-1 Agonist 20%
• Apoplexy 20%
• Mortality 20%
• Glucosidase 20%
• Microvascular Complication 20%
• Therapeutic Procedure 20%
• Incidence 20%
• Patient 20%
• Inpatient 20%
• Plasma 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Glucose 100%
• Cardiovascular Risk 40%
• Drug 40%
• Clinical Trial 40%
• Insulin 20%
• Morbidity 20%
• Diabetes Mellitus 20%
• Heart Infarction 20%
• Sodium Glucose Cotransporter 2 Inhibitor 20%
• Hypoglycemia 20%
• Sulfonylurea 20%
• Glucagon Like Peptide 1 Receptor Agonist 20%
• Hemoglobin A1c 20%
• Mortality 20%
• Glucosidase 20%
• Incidence 20%